Glenmark Pharmaceuticals launches ‘Lobeglitazone' in India

6 Oct 2022 , 10:56 AM

Glenmark Pharmaceuticals Limited, a worldwide pharmaceutical company focused on innovation, became the first company to introduce Thiazolidinedione Lobeglitazone (Lobeglitazone) in India for the treatment of type 2 diabetes in adults.

It is marketed under the brand name LOBG and is to be taken once a day under prescription to enhance glycemic control in adult diabetes patients. Because Indians have a high frequency of insulin resistance, LOBG is an intriguing therapy option for uncontrolled Type 2 diabetes in insulin-resistant diabetic individuals.

Glenmark previously got approval from the Indian pharma authority, the Drug Controller General of India, to manufacture and distribute Lobeglitazone based on a randomised, double-blind Phase 3 clinical study on adult Type 2 diabetes patients aged 18 and older. Lobeglitazone demonstrated quicker and better glycemic management in this experiment.

According to IQVIA sales statistics for the 12month period ending August 2022, the market for oral antidiabetic medications in India is anticipated to reach Rs11,725 crore, representing a 7% annual rise over the same time last year (MAT Aug 2021).

At around 11.00 AM, Glenmark Pharmaceuticals was trading at Rs403.60 down by 0.09% from its previous closing of Rs403.95 on the BSE. The scrip opened at Rs406.90 and touched intraday high and low of Rs409.40 and Rs402.50 respectively.

For feedback and suggestions, write to us at [e-mail]